Scleroderma Treatment and Management

The management of systemic sclerosis has evolved into a sophisticated, organ-specific strategy that integrates pharmacological intervention with rehabilitative and regenerative approaches. There is currently no single cure that reverses the disease entirely, but modern medicine offers potent tools to modify its course, manage symptoms, and prevent severe complications. The treatment philosophy follows a “treat to target” model, aiming to suppress inflammation, stabilize vascular function, and halt the progression of fibrosis. The therapeutic regimen is highly personalized, determined by the specific disease subtype (limited versus diffuse) and the organs involved.

Central to this strategy is the concept of vascular rescue. Since vascular injury initiates the disease, maintaining blood flow is critical. This involves aggressive vasodilator use. Calcium channel blockers are the first-line therapy for Raynaud’s phenomenon, relaxing the smooth muscles of the arterial wall. For more severe vascular ischemia or digital ulcers, phosphodiesterase type 5 inhibitors and endothelin receptor antagonists are employed. These advanced agents not only improve peripheral circulation but also serve as the cornerstone of treating pulmonary arterial hypertension, helping reduce strain on the right heart and improve exercise tolerance.